Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.

The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.

Relay Therapeutics (RLAY) has appointed Claire Mazumdar, Ph.D., to its Board of Directors effective June 9, 2025. Dr. Mazumdar brings significant experience in clinical-stage oncology and will provide guidance for the company's upcoming Phase 3 ReDiscover-2 breast cancer trial. She currently serves as the founding CEO of Bicara Therapeutics (BCAX) and previously led business development at Rheos Medicines, where she managed a global partnership with Roche Pharmaceuticals. Her background includes a role at Third Rock Ventures focusing on company formation, along with degrees from MIT (B.S. in biological engineering) and Stanford (MBA and Ph.D. in cancer biology).

Relay Therapeutics (RLAY) presented updated interim clinical data for RLY-2608, their pioneering allosteric, pan-mutant and isoform-selective PI3Kα inhibitor, at ASCO 2025. The data showed a median progression-free survival (PFS) of 10.3 months overall and 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer when combined with fulvestrant. With 12.5 months median follow-up, the study demonstrated a 67% clinical benefit rate and 39% confirmed objective response rate among patients with measurable disease. The drug maintained a favorable safety profile with 92% median dose intensity and mostly low-grade treatment-related adverse events. The company plans to initiate the Phase 3 ReDiscover-2 trial in mid-2025 and is advancing two front-line triplet regimens with CDK4/6 inhibitors.

Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 8:45 a.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:40 p.m. ET. Both presentations will be accessible via live webcast through Relay's website, with recordings available for 30 days after each event.

Relay Therapeutics (NASDAQ: RLAY) reported Q1 2025 financial results and corporate updates, highlighting strategic cost reductions that extend cash runway into 2029. The company ended Q1 with $710.3 million in cash and investments. Key developments include the upcoming Phase 3 ReDiscover-2 trial initiation in mid-2025 and the launch of Phase 1 RLY-2608 vascular malformations trial in Q1. Significant cost-cutting measures implemented include an 80% reduction in research run rate spend, reducing research programs from four to one, and a workforce reduction of approximately 70 people. Q1 financial results showed revenue of $7.7 million, R&D expenses of $73.8 million, and a net loss of $77.1 million ($0.46 per share).

Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its first quarter 2025 financial results and corporate highlights on Monday, May 5, 2025. The announcement will be made after U.S. financial markets close.

The company, based in Cambridge, Massachusetts, specializes in transforming drug discovery through a combination of:

• Leading-edge computational technologies
• Experimental technologies

This upcoming financial disclosure represents a standard quarterly reporting event for the precision medicine developer, providing stakeholders with insights into the company's financial performance and operational progress for Q1 2025.

Relay Therapeutics (RLAY) reported its Q4 and full year 2024 financial results, highlighting progress in its breast cancer program. The company plans to initiate the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025 for PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.

Key clinical data showed 11.4-month median PFS in second-line patients, with a 39% confirmed overall response rate and 67% Clinical Benefit Rate. The company ended Q4 2024 with $781.3 million in cash and investments, expected to fund operations into second half of 2027.

Financial results showed no revenue in Q4 2024, while full-year revenue decreased to $10.0 million from $25.5 million in 2023. R&D expenses were $68.1 million in Q4 2024, down from $77.5 million in Q4 2023. Net loss for Q4 2024 was $76.0 million ($0.45 per share), compared to $83.5 million ($0.67 per share) in Q4 2023.

Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in March 2025. The company will be featured in fireside chat sessions at:

• TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 11:00 a.m. ET

Both sessions will be accessible via live webcast through Relay Therapeutics' website in the News & Events section. Archived recordings will remain available for 30 days after each event. The company, known for combining computational and experimental technologies in drug discovery, makes these presentations available at https://ir.relaytx.com/news-events/events-presentations.

Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, announced it will release its fourth quarter and full year 2024 financial results and corporate highlights on Wednesday, February 26, 2025, after U.S. market close. The company specializes in combining computational and experimental technologies for drug discovery.